Benzinga | May 25, 2021 06:45AM EDT

Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $150

Barclays analyst Travis Steed initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $150.